BRC Therapeutics Appoints Veteran Pharma Executive Ron Eastman to Board of Directors
核心洞察
BRC Therapeutics (搜索) has appointed Ron Eastman, a pharmaceutical executive with over 40 years of drug development and investment experience, to its Board of Directors.
Mr. Eastman previously served as CEO of Geron Corporation and Rinat Neuroscience (搜索), and most recently as Senior Advisor at EW Healthcare Partners (搜索).
His appointment comes as BRC advances multiple assets through clinical development, including the recent FDA clearance of an IND for BRC-002 in Complex Regional Pain Syndrome (搜索).
BRC Therapeutics (搜索), a Monterey-based pharmaceutical company focused on neurological and inflammatory diseases, announced the appointment of Ron Eastman to its Board of Directors. Mr. Eastman brings more than four decades of experience spanning pharmaceutical operations, drug development, and life sciences investing across both private and public companies.
"We are delighted to welcome Ron to our Board. His depth of experience across the life cycle of therapeutics development and commercialization makes him an exceptional addition to our team," said George Hodgin, CEO and Founder of BRC Therapeutics (搜索). "As we advance several assets through clinical development, his expertise and guidance will be invaluable to the company."
A Career Spanning Drug Development and Investment
Mr. Eastman currently serves as Senior Advisor at EW Healthcare Partners (搜索), one of the most established healthcare- and life sciences-focused investment firms in the industry, where he previously served as Managing Director across multiple funds. During his tenure at EW Healthcare Partners, he led investments in ProteinSimple (acquired by Bio-Techne), Corium Therapeutics (acquired by Gurnet Point), Revance Therapeutics (acquired by Crown Laboratories), EyePoint Pharmaceuticals, and Elusys Therapeutics (acquired by Heat Biologics).
Prior to his investment career, Mr. Eastman served as CEO of Geron Corporation, where he led the company's growth from a venture-backed startup to a publicly traded pioneer in regenerative medicine and oncology. He subsequently served as CEO of Rinat Neuroscience (搜索), a Genentech spin-out focused on developing large molecule therapeutics for nervous system disorders, which was acquired by Pfizer in 2006. He began his career at American Cyanamid Company (acquired by American Home Products, now Pfizer), where he spent 15 years managing pharmaceutical products, divisions, and subsidiaries across the United States and internationally. Mr. Eastman holds a Bachelor of Arts from Williams College and a Master of Business Administration from Columbia University.
BRC's Clinical Pipeline and Strategic Momentum
"BRC Therapeutics (搜索) is addressing significant unmet medical needs with an innovative first-in-class approach," said Ron Eastman. "I am impressed by the science, the team, and the clinical and regulatory progress BRC has achieved — most recently the FDA's clearance of the IND for BRC-002 in Complex Regional Pain Syndrome (搜索). BRC's differentiated proposition may transform how patients will be treated in the future. I look forward to supporting the company as it enters its next stage of growth."
BRC Therapeutics (搜索) develops multimodal medicines containing cannabinoids at defined ratios, with a pipeline of investigational prescription medicines addressing neurological and inflammatory conditions. Two investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (搜索) (CRPS) and Aromatase Inhibitor-Induced Arthralgia (搜索) (AIIA). The company is registered with the Drug Enforcement Administration and is based in Monterey, California.